• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 14, 2015

View Archived Issues

Medicines Company gets a boost as ‘Cangrelor looks approvable’

FDA briefing documents posted ahead of Wednesday’s meeting of the Cardiovascular and Renal Drugs Advisory Committee (adcom) meeting to review the approvability of cangrelor were sufficiently positive to give shares of The Medicines Co. (NASDAQ:MDCO) a modest boost Monday. Read More

Taxus Cardium taps Chinese investor for new firm Angionetics

Taxus Cardium Pharmaceuticals Group Inc. inked a new deal with its Chinese investor to help fund a recently launched subsidiary aimed at advancing Generx (alferminogene tadenovec [Ad5FGF-4]), an angiogenic gene therapy candidate that has been in development for nearly 20 years, but may be finally reaching the finish line just as interest is reigniting the overall space. Read More

Under-fire IMI is still waiting for new director

DUBLIN – The ongoing delay in appointing a new executive director to the Innovative Medicines Initiative (IMI), Europe’s €3.3 billion (US$2.1 billion) public-private partnership on drug research, shows no immediate signs of ending, while its interim director, EC official Irene Norstedt, has defended the initiative against a major media onslaught led by Germany’s influential current affairs magazine Der Spiegel. Read More

European drug regulation: Past, present and future

PARIS – Better patient safety has been the single greatest benefit of Europe’s system of pharmaceuticals regulation and legislation over the past 50 years, according to an audience vote at a Regulatory Town Hall meeting, which kicked off proceedings at the Drug Information Association’s (DIA) 27th annual European meeting at Le Palais des Congrès in Paris, Monday. Read More

Hold your Norses: Viking downgrades IPO to raise Ligand deal-sparing cash

As an advisory panel for the FDA prepared to take up the matter Tuesday of safety issues with Astrazeneca plc’s marketed dipeptidyl peptidase-4 (DPP-4) inhibitor for diabetes, Viking Therapeutics Inc. lowered the target for its IPO in a move that could help the firm advance the licensing deal with Ligand Pharmaceuticals Inc. – also with a strong diabetes component, though otherwise unrelated and involving drugs with a different mechanism of action). Read More

Biopharma firms ride Hong Kong and Shanghai bull markets

HONG KONG – China-focused biopharmaceutical stocks have not been left out of the bull markets in Hong Kong and Shanghai, which are being powered by an influx of capital and strong company performances. Read More

Restoring balance in the coagulation cascade

Researchers for Alnylam Pharmaceuticals Inc. have published preclinical data for the company’s investigational hemophilia treatment ALN-AT3, which is currently undergoing phase I clinical testing and represents “a different approach to managing hemophilia,” senior author Akin Akinc told BioWorld Today. Read More

Regulatory front

Per a request from the U.S. Trade Representative (USTR), the World Trade Organization (WTO) will establish a dispute settlement panel at its April 22 meeting to consider China’s Demonstration Bases-Common Service Platform export subsidy program. Read More

Stock movers

Read More

Financings

TVM Capital Life Science, of Montreal, said it has achieved the first closing of China Biopharma Capital I at $50 million with subscription from Chongqing Lummy Pharmaceutical Co., Ltd., a pharmaceutical company based in Chongqing, China. Read More

Other news to note

Bone Therapeutics SA, of Gosselies, Belgium, said it has established a U.S.-based subsidiary, Bone Therapeutics USA Inc. in Boston that will enable them to move forward with its U.S. clinical trials program for fracture repair and osteonecrosis. Read More

In the clinic

Cytori Therapeutics Inc., of San Diego, reported preliminary follow-up data from the 12-patient, investigator-initiated Scleradec-I trial, showing no reports of adverse events or safety concerns with cell therapy candidate ECCS-50. Read More

Pharma: Other news to note

Mylan NV, of Potters Bar, UK, said it provided Perrigo Co. plc, of Dublin, with notice of its filing of the premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe